An open trial of reboxetine in obese patients with binge eating disorder.

@article{Silveira2005AnOT,
  title={An open trial of reboxetine in obese patients with binge eating disorder.},
  author={Raphael de Oliveira Pessoa Silveira and Vanessa Cassina Zanatto and Jos{\'e} Carlos Appolin{\'a}rio and Fl{\'a}vio Kapczinski},
  journal={Eating and weight disorders : EWD},
  year={2005},
  volume={10 4},
  pages={e93-6}
}
BACKGROUND The objective of this study was to evaluate the effectiveness and safety of reboxetine, a selective noradrenaline reuptake inhibitor, in the treatment of obese patients with binge eating disorder (BED). METHOD Nine outpatients with BED and obesity received reboxetine 8 mg/day for 12 weeks. The number of days with binge eating episodes per week was considered the primary outcome measure. Body weight, body mass index (BMI), Binge Eating Scale (BES), Clinical Global Impression… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS